Cambridge Healthtech Institute’s 3rd Annual

Cell Line Development to Protein Expression

From Gene to Industrial Use

25-26 March 2020

 

The foundations of protein production will be explored in Cambridge Healthtech Institute’s Cell Line Development to Protein Expression conference. What are the steps needed to develop a productive cell line that meets project goals? Each protein and each expression system is different, so which is best to use? This conference will examine the steps that are necessary to establish productive cell lines that ensure robust expression to support the industry’s growing needs.

Preliminary Agenda

STRATEGIES TO BOOST PRODUCTIVITY

FEATURED PRESENTATION: Manipulating the Epitranscriptome as a Means to Impact Recombinant Protein Production in Mammalian Cells

Niall Barron, PhD, Professor, Principal Investigator, Cell Engineering, National Institute for Bioprocessing Research and Training (NIBRT)

Strategies for Production and Characterization of Multi-Protein Complexes: Top-Down vs Bottom-Up Strategies

Arnaud Poterszman, PhD, Research Director, Integrated Structural Biology, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC)

Ways to Increase Throughput in Developing Stable Cell Lines for Biopharm Use

Gabriela Kozejova, Senior Scientist, Protein and Cellular Sciences, R&D Platform Technology & Science, GSK Medicines Research Centre

An Improved Cell Line Development Process for the Expression of mAbs and BEAT Antibodie

Martin Bertschinger, PhD, Deputy Director, Cell Sciences, Glenmark Pharmaceuticals

ENHANCING CHO ENGINEERING

Engineering of Multiple Metabolic Pathways Mediates Improved Productivity in CHO Cells

Nicolas P. Mermod, PhD, Professor and Director, Biology & Medicine, The University of Lausanne

Glycoengineering CHO Cell Lines for the Production of Hard-to-Produce Glycoproteins

Bjørn Voldborg, MSc, Director, CHO Core, The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark (DTU)

Rapid Selection of CHO Clones Secreting Recombinant Antibodies

Bert Devriendt, PhD, Scientist, Virology, Parasitology, Immunology, Physiology, Ghent University

CHO Cells Characterisation and Manipulation for Increased Recombinant Protein Production

Eva Pekle, PhD, Associate Scientist, Process Development, Achilles Therapeutics, Ltd. 

CELL LINE ENGINEERING INSIGHTS

A Generic Process for the Production of kl Body Mixtures from a Single Cell Line

Yves Poitevin, MSc, Head, Bioprocessing Unit, Light Chain Bioscience (a brand of NovImmune S.A.)

Do’s and Don’ts in Translating Cell Line Research from Academia to Biotech

Tsafi Danieli, PhD, Head, Protein Expression Core Facility, Wolfson Center for Applied Structural Biology, The Hebrew University of Jerusalem

TARGETED APPROACHES TO ENGINEERING CELL LINES

Continuous Production with E. coli – USP Concepts and Strategies

Gerald Striedner, PhD, Associate Professor, Biotechnology, University of Natural Resources and Life Sciences, Vienna (BOKU)

Glycoengineering of the Human Embryonic Kidney FreeStyle 293-F Cell Line towards Improved Bioavailablity of Recombinant Coagulation Factor VII 

Rico Uhler, PhD, Scientist, Cell Line Development, Mannheim University of Applied Sciences, and Octapharma Biopharmaceuticals GmbH

Stable Viral Vector-Producing Cell Lines for Cell and Gene Therapy

Mark Chen, PhD, Manager, Cell Line Development, Cell and Gene Therapy Product Development, GSK R&D




For more details on the conference, please contact:
Mary Ruberry

Senior Conference Director

Cambridge Healthtech Institute

Phone: 1-781-972-5421

Email: mruberry@healthtech.com

 

For partnering and sponsorship information, please contact:

Companies A-K

Sherry Johnson

Business Development Manager

Cambridge Healthtech Institute

Phone: 781-972-1359

Email: sjohnson@cambridgeinnovationinstitute.com

 

Companies L-Z

Carolyn Cooke

Business Development Manager

Cambridge Healthtech Institute

Phone: 781-972-5412

Email: ccooke@healthtech.com